RESUMEN
PURPOSE OF THE STUDY: Invasive aspergillosis (IA) is the most prevalent invasive fungal disease (IFD) in neutropenic patients. Environment is the main source of Aspergillus spores aerosolization especially during building construction. International guidelines recommend mechanical protection during hospital building works; otherwise the use of antifungal prophylaxis is not clearly indicated. Our objective was to determine the efficacy of antifungal prophylaxis by posaconazole on IA incidence in acute myeloid leukemia population and to analyse the benefit of this prophylaxis and HEPA-filters during hospital buildings works. PATIENTS AND METHODS: We included patients treated for acute myeloid leukemia at Brest teaching hospital from January 2009 to December 2015. We compared incidence of IA in the group treated by posaconazole from 2012 to 2015 to the incidence of IA in the first group who did not receive antifungal prophylaxis (from 2009 to 2011). The one-year overall survival was also analyzed using the Kaplan-Meier method. RESULTS: 245 patients were enrolled including 151 treated with posaconazole. 23 IA were diagnosed between 2009 and 2011 (without antifungal prophylaxis), then 31 between 2012 and 2015 (with posaconazole) without statistical difference between the incidence densities (0.34 per 100 hospitalization-days vs. 0.30 per 100 hospitalization-days, p = 0.71). Incidence density of IA increased during building works (2.40 per 100 hospitalization-days vs. 0.28 per 100 hospitalization-days, p < 0.0001). The incidence density of IA significantly decreased during construction periods when posaconazole prophylaxis was used (1.59 per 100 hospitalization-days vs. 4.87 per 100 hospitalization-days p < 0.0001). CONCLUSION: Our study suggests, for the first time, the interest of antifungal prophylaxis in addition to HEPA filtration in prevention of IA during hospital building works.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/prevención & control , Infecciones Fúngicas Invasoras/prevención & control , Leucemia Mieloide Aguda/complicaciones , Triazoles/uso terapéutico , Adulto , Aerosoles , Filtros de Aire , Microbiología del Aire , Contaminación del Aire Interior , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Aspergilosis/epidemiología , Aspergillus/efectos de los fármacos , Aspergillus/aislamiento & purificación , Aspergillus/fisiología , Terapia Combinada , Exposición a Riesgos Ambientales , Neutropenia Febril/complicaciones , Femenino , Filtración , Francia , Trasplante de Células Madre Hematopoyéticas , Arquitectura y Construcción de Hospitales , Hospitales de Enseñanza , Humanos , Incidencia , Infecciones Fúngicas Invasoras/epidemiología , Estimación de Kaplan-Meier , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/terapia , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Estudios Retrospectivos , Esporas FúngicasRESUMEN
Vaccines rank among the greatest advances in the history of public health. Yet, despite the need, there are no licensed vaccines to protect humans against fungal diseases, including aspergillosis. In this focused review, some of the major scientific and logistical challenges to developing vaccines to protect at-risk individuals against aspergillosis are discussed. Approaches that have shown promise in animal models include vaccines that protect against multiple fungal genera and those that are specifically directed to Aspergillus Advances in proteomics and glycomics have facilitated identification of candidate antigens for use in subunit vaccines. Novel adjuvants and delivery systems are becoming available that can skew vaccine responses toward those associated with protection. Immunotherapy consisting of adoptive transfer of Aspergillus-specific T cells to allogeneic hematopoietic transplant recipients has advanced to human testing but is technically difficult and of unproven benefit. While progress has been impressive, much work still needs to be done if vaccines against aspergillosis are to become a reality.
Asunto(s)
Aspergilosis/prevención & control , Aspergillus/inmunología , Vacunas Fúngicas/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Animales , Aspergilosis/inmunología , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Vacunas Fúngicas/administración & dosificación , Humanos , Inmunización Pasiva , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/inmunologíaRESUMEN
There is a strong argument for the use of antifungal prophylaxis in high-risk patients given the significant mortality associated with invasive fungal disease, the late identification of these infections, and the availability of safe and well-tolerated prophylactic medications. Clinical decisions about which patients should receive prophylaxis and choice of antifungal agent should be guided by risk stratification, knowledge of local fungal epidemiology, the efficacy and tolerability profile of available agents, and estimates such as number needed to treat and number needed to harm. There have been substantial changes in practice since the 2008 guidelines were published. These include the availability of new medications and/or formulations, and a focus on refining and simplifying patient risk stratification. Used in context, these guidelines aim to assist clinicians in providing optimal preventive care to this vulnerable patient demographic.
Asunto(s)
Antifúngicos/uso terapéutico , Neoplasias Hematológicas/inmunología , Trasplante de Células Madre Hematopoyéticas , Infecciones Oportunistas/microbiología , Infecciones Oportunistas/prevención & control , Profilaxis Pre-Exposición , Aspergilosis/prevención & control , Candidiasis/prevención & control , Consenso , Análisis Costo-Beneficio , Adhesión a Directriz , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/terapia , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Pruebas de Sensibilidad Microbiana , Selección de Paciente , Guías de Práctica Clínica como Asunto , Profilaxis Pre-Exposición/economía , Medición de RiesgoRESUMEN
BACKGROUND: Universal antifungal prophylaxis with azoles is commonly used after lung transplantation. We noted an increase in isolates of Aspergillus calidoustus in our transplant population and hypothesized that increasing azole use (universal prophylaxis since 2008) may be promoting this infection. METHODS: Clinical and microbiologic data for A. calidoustus cases from 2008 to 2011 were extracted from chart review. For lung transplant patients, a case-control study was performed to determine risk factors, and incidence rates were calculated. RESULTS: From 2008 to 2011, we identified seven organ transplant recipients and one hematopoietic stem-cell transplant patient with positive A. calidoustus culture results in bronchoalveolar lavage at a median of 13 months after transplantation (interquartile range, 4-39 months). Chest computed tomographic scan was consistent with fungal infection in six of eight patients, and the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria classified these as "probable" invasive aspergillosis. In the case-control study, there were no differences in immunosuppression, number of respiratory samples taken, length of intensive care unit stay, or rejection rates. Of controls, 33.3% received third-generation azole prophylaxis compared with 83.3% of cases (P=0.13). However, median duration of exposure was greater in cases than in controls (3 vs. 0 months, P=0.045). Fungal minimum inhibitory concentration for voriconazole was 4 µg/mL or greater for six of eight cases. Incidence rates in lung transplants showed an increase of A. calidoustus (0/1000 vs. 11.3/1000 patient-years in 2006-2007 and 2008-2011, respectively; P=0.018), whereas Aspergillus fumigatus cases decreased (73.9/1000 vs. 49.0/1000 patient-years, P=0.0066). CONCLUSIONS: Pulmonary A. calidoustus seems to be an emerging pathogen mainly in lung transplants. We suggest that third-generation azole use reduced the incidence of A. fumigatus, but the incidence of A. calidoustus, an azole-resistant fungus, was increased.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/prevención & control , Trasplante de Pulmón/efectos adversos , Adulto , Anciano , Aspergilosis/diagnóstico , Aspergilosis/etiología , Aspergillus/aislamiento & purificación , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Pirimidinas/uso terapéutico , Estudios Retrospectivos , Factores de Riesgo , Triazoles/uso terapéutico , VoriconazolRESUMEN
Itraconazole is used for the prevention and treatment of infections caused by Aspergillus fumigatus. An understanding of the pharmacodynamics of itraconazole against wild-type and triazole-resistant strains provides a basis for innovative therapeutic strategies for treatment of infections. An in vitro model of the human alveolus was used to define the pharmacodynamics of itraconazole. Galactomannan was used as a biomarker. The effect of systemic and airway administration of itraconazole was assessed, as was a combination of itraconazole administered to the airway and systemically administered 5FC. Systemically administered itraconazole against the wild type induced a concentration-dependent decline in galactomannan in the alveolar and endothelial compartments. No exposure-response relationships were apparent for the L98H, M220T, or G138C mutant. The administration of itraconazole to the airway resulted in comparable exposure-response relationships to those observed with systemic therapy. This was achieved without detectable concentrations of drug within the endothelial compartment. The airway administration of itraconazole resulted in a definite but submaximal effect in the endothelial compartment against the L98H mutant. The administration of 5FC resulted in a concentration-dependent decline in galactomannan in both the alveolar and endothelial compartments. The combination of airway administration of itraconazole and systemically administered 5FC was additive. Systemic administration of itraconazole is ineffective against Cyp51 mutants. The airway administration of itraconazole is effective for the treatment of wild-type strains and appears to have some activity against the L98H mutants. Combination with other agents, such as 5FC, may enable the attainment of near-maximal antifungal activity.
Asunto(s)
Antifúngicos/farmacología , Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Itraconazol/farmacología , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Alveolos Pulmonares/microbiología , Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Aspergilosis/microbiología , Aspergilosis/prevención & control , Células Cultivadas , Vías de Administración de Medicamentos , Farmacorresistencia Fúngica , Flucitosina/administración & dosificación , Flucitosina/farmacología , Galactosa/análogos & derivados , Humanos , Itraconazol/administración & dosificación , Itraconazol/farmacocinética , Enfermedades Pulmonares Fúngicas/microbiología , Mananos/análisis , Pruebas de Sensibilidad Microbiana , Triazoles/farmacologíaRESUMEN
Immunosuppressed patients are at high risk of acquiring airborne fungal infections, mainly caused by Aspergillus species. Although HEPA filters are recommended to prevent environmental exposure, mobile air-treatment units can be an alternative. However, many different models of mobile units are available but there are few data on their fungal aero-decontamination efficacy and usefulness in the prevention of Aspergillus infections. Thus, we developed a challenge test, based on the aerosolization of 10(6) Aspergillus niger conidia, in order to compare the particle and fungal decontamination efficacy of the following four mobile air-treatment systems; Plasmair T2006, Mobil'Air 1200 (MA1200), Mobil'Air 600 (MA600) combined with Compact AirPur Mobile C250 (C250), and the prototype unit Compact AirPur Mobile 1800 (C1800). The use of all these air-treatment systems was able to significantly decrease the concentration of particles or fungal viable conidia. ISO7 was the maximum particle class reached within 20 min with the Plasmair T2006 and MA1200, 1 h by the combined MA600/C250, and 1 h and 30 min with the C1800. After 2 h, fungal counts were significantly lower with Plasmair T2006, MA1200 and the combined MA600/C250 (2.2 ± 1.9 to 5.0 ± 3.7 CFU/m(3)) than achieved with the C1800 (23.8 ± 12.8 CFU/m(3); P ≤ 6.0E-3). All the air-treatment systems were able to decrease aerial particle and fungal counts, but their efficacy was variable, depending on the units' air-treatment modalities and rates of air volume that was processed. This comparative study could be helpful in making an informed choice of mobile units, and in improving the prevention of air-transmitted fungal infections in non-protected areas.
Asunto(s)
Aire Acondicionado/instrumentación , Contaminación del Aire Interior/prevención & control , Aspergilosis/prevención & control , Aspergillus niger/aislamiento & purificación , Descontaminación/instrumentación , Control de Infecciones/instrumentación , Microbiología del Aire , Contaminantes Atmosféricos , Aspergilosis/microbiología , Recuento de Colonia Microbiana , Hongos/aislamiento & purificación , Humanos , Esporas FúngicasRESUMEN
Invasive fungal infections (IFIs) are a frequent, costly and potentially life-threatening complication in hematopoietic stem cell transplant (HSCT) recipients. Most prevalent among the causative pathogens are Candida spp. and Aspergillus spp. Risk factors that further increase the risk of IFIs in this patient population include allogeneic transplant and acute graft versus host disease. Among strategies to improve outcomes is the administration of antifungal prophylaxis. However, optimal administration requires the identification of patients who are at the highest risk of developing a fungal infection, thus restricting concerns of drug cost, toxicity and resistance to those most likely to benefit. Currently, there are several antifungal agents recommended by the National Comprehensive Cancer Network for the prophylaxis of IFIs. These include fluconazole, itraconazole, voriconazole, posaconazole and micafungin. Fluconazole was widely considered the standard agent for prophylaxis in patients at lower risk of mold infections. New data support the efficacy of the newer triazole posaconazole and the echinocandin micafungin in this patient population..
Asunto(s)
Antifúngicos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Micosis/prevención & control , Adulto , Aspergilosis/etiología , Aspergilosis/prevención & control , Candidiasis/etiología , Candidiasis/prevención & control , Humanos , Micosis/etiologíaRESUMEN
Chronic Granulomatous Disease (CGD) is a rare disorder caused by mutations in the NADPH oxidase. The CGD phenotype includes granuloma formation and susceptibility to infection with microorganisms including Aspergillus. The immune adjuvant interferon-gamma and the antifungal agent itraconazole have reduced the incidence of infections in CGD. Studies using CGD phagocytes have shown that reactive oxygen species (ROS), products of the NAPDH oxidase, are critical for killing Aspergillus hyphae. But despite lack of ROS production, CGD patients generally only get infected with Aspergillus after heavy exposure. To study why CGD patients are not infected with Aspergillus more frequently we studied host defense against this ubiquitous mold further. We found that neutrophil lactoferrin is fungistatic for Aspergillus fumigatus spores by chelation of iron, an essential growth factor. Thus, the neutrophil employs both nonoxidative (lactoferrin) and oxidative (hydrogen peroxide) defense mechanisms against A. fumigatus spores and hyphae, respectively.
Asunto(s)
Aspergilosis/etiología , Aspergilosis/terapia , Enfermedad Granulomatosa Crónica/complicaciones , Enfermedad Granulomatosa Crónica/terapia , Antifúngicos/uso terapéutico , Aspergilosis/prevención & control , Aspergillus/inmunología , Aspergillus/patogenicidad , Humanos , Quelantes del Hierro/uso terapéutico , Lactoferrina/fisiología , Fagocitos/fisiología , Especies Reactivas de Oxígeno/metabolismoRESUMEN
OBJECTIVE: Despite the promising preliminary results observed in extremely low birth weight (ELBW) populations, the use of fluconazole to prevent fungal colonization and infection in preterm neonates in the NICU is still an open question and not yet recommended as a standard of care. We have reviewed our 6-year series to assess the effectiveness and safety of this form of prophylaxis. METHODS: This retrospective study consisted of 465 neonates who weighed < 1500 g at birth and were admitted to our NICU in the period 1998-2003. Those who were born between 1998 and 2000 and did not receive fluconazole prophylaxis (group A, n = 240) were compared with those who were born between 2001 and 2003 and treated with fluconazole until the 30th day of life (45th for neonates < 1000 g at birth; group B, n = 225). Weekly surveillance cultures were obtained from all patients. Incidence of fungal colonization, incidence of systemic fungal infection (SFI), rate of progression from colonization to infection, and mortality rates attributable to fungi were calculated for both groups and separately for neonates who were < 1000 g (ELBW) and were 1001 to 1500 g (NE-VLBW) at birth. RESULTS: Overall fungal colonization was significantly lower in group B (24.0%) than in group A (43.8%; relative risk [RR]: 0.406; 95% confidence interval [CI]: 0.273-0.605). The same was true of neonates with colonization in multiple sites (2.6% vs 5.8%) and of those with colonization from high-risk sites (5.8% vs 19.2%). SFI incidence was significantly lower in group B (10 of 225 cases; 4.4%) than in group A (40 of 240 cases; 16.7%; RR: 0.233; 95% CI: 0.113-0.447). Reduction of both colonization and SFI in group B was greater in the ELBW neonates and also significant in the NE-VLBW neonates. Rate of progression from colonization to infection was significantly lower in group B (0.17 vs 0.38; RR: 0.369; 95% CI: 0.159-0.815). Crude mortality rate attributable to Candida species was 1.7% (4 of 240) in group A vs 0% (0 of 225) in group B. Overall mortality rate (any cause before hospital discharge) was similar in the two groups (11.2% vs 10.6%), but in colonized infants (n = 159), it was significantly lower in group B (3.7% vs 18.1%; RR: 0.174; 95% CI: 0.039-0.778). The incidence of natively fluconazole-resistant fungal species did not increase over the years, and patterns of sensitivity to fluconazole remained the same. No adverse reaction related to fluconazole occurred. CONCLUSIONS: Prophylactic fluconazole significantly reduces the incidence of colonization and systemic infection by Candida species in both ELBW and NE-VLBW neonates and decreases the rates of progression from initial colonization to massive colonization and to systemic infection. All VLBW neonates may benefit from fluconazole prophylaxis.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/prevención & control , Candidiasis/prevención & control , Fluconazol/uso terapéutico , Enfermedades del Prematuro/prevención & control , Antifúngicos/efectos adversos , Candida/efectos de los fármacos , Fluconazol/efectos adversos , Humanos , Recién Nacido , Recién Nacido de muy Bajo Peso , Pruebas de Sensibilidad MicrobianaRESUMEN
Invasive aspergillosis (IA) can occur despite prior prophylactic or empiric use of triazoles or amphotericin B (AMB). Although profound immunosuppression may account for breakthrough IA, resistance of Aspergillus to antifungals may also play a role. To examine this question, we measured the minimal inhibitory concentration of 105 Aspergillus isolates recovered from 105 cancer patients (64 with IA, 41 with Aspergillus colonization) to AMB, itraconazole (ITC), and voriconazole (VRC) using the National Committee for Clinical Laboratory Standards (NCCLS) M38-A microdilution and E-test methods. We also determined the minimal fungicidal concentration (MFC) of these agents and the minimal effective concentration (MEC) of caspofungin (CAS) using standardized methods. We then collected information regarding pre-exposure to AMB or triazoles (fluconazole, ITC, VRC) within 3 months before Aspergillus isolation. Pre-exposure of cancer patients to AMB or triazoles was associated with increased frequency of non-fumigatus Aspergillus species. Aspergillus isolates recovered from patients who previously received AMB exhibited higher E-test AMB MICs compared with isolates from patients without prior AMB exposure (P = 0.01). In addition, the AMB MICs by E-test were higher in triazole-pre-exposed patients compared with those not exposed to triazoles (P = 0.001). The ITC and VRC MICs by E-test were not affected by prior AMB or triazole exposure. Finally, neither the AMB, ITC, and VRC MICs and MFCs by NCCLS method nor CAS MECs showed such changes. In conclusion, cancer patients with positive Aspergillus cultures who are pre-exposed to AMB or triazoles have high frequency of non-fumigatus Aspergillus species. These Aspergillus isolates were found to be AMB-resistant by the more sensitive E-test method.
Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Aspergilosis/prevención & control , Aspergillus/clasificación , Neoplasias/tratamiento farmacológico , Triazoles/uso terapéutico , Anfotericina B/farmacología , Aspergillus/efectos de los fármacos , Aspergillus/aislamiento & purificación , Quimioprevención , Medios de Cultivo , Farmacorresistencia Fúngica , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Triazoles/farmacologíaRESUMEN
In the present study, we evaluated the immunopotentiating efficacy of tuftsin against experimental murine aspergillosis in both normal and immunodebilitant BALB/c mice. The animals were challenged with an isolate of Aspergillus fumigatus (1x10(8) cfu/mouse) that was showing less susceptibility to lower doses of amphotericin B in murine animal model. Co-administration of the immunomodulator tuftsin and liposomised-amphotericin B was found to be highly effective in the treatment of systemic infection of A. fumigatus in both immunocompetent and leukopenic mice. Moreover, pre-treatment of mice with liposomised-tuftsin prior to challenging them with A. fumigatus infection and subsequent treatment with tuftsin-bearing liposomised-amphotericin B was found to be extremely efficient in successful elimination of fungal pathogen. In another set of experiments, tuftsin-mediated antigen-specific memory antibody response was also assessed by immunizing the animals with A. fumigatus cytosolic antigen. The animals that received a booster 150 days after the first immunization with tuftsin-liposomes-antigen showed more resistance to A. fumigatus infection in comparison with the naïve animals.
Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Aspergilosis/inmunología , Aspergilosis/prevención & control , Aspergillus fumigatus , Factores Inmunológicos/uso terapéutico , Tuftsina/uso terapéutico , Anfotericina B/farmacología , Animales , Antifúngicos/farmacología , Aspergillus fumigatus/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Huésped Inmunocomprometido , Factores Inmunológicos/farmacología , Liposomas , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad MicrobianaRESUMEN
OBJECTIVES: To describe and investigate the cause of an outbreak of 10 cases of nosocomial invasive infection with Aspergillus flavus in a hematologic oncology patient care unit. DESIGN: A retrospective cohort study. SETTING: The hematologic oncology unit of a comprehensive cancer center. PATIENTS: Ninety-one patients admitted to the hematologic oncology service between January 1 and December 31, 1992, for 4 or more consecutive days were included in the study. RESULTS: Ten (18%) of 55 patients admitted from July to December 1992 were diagnosed as having invasive aspergillosis compared with 0 (0%) of 36 patients admitted from January to June 1992 to the same patient care units. Patient characteristics, mortality rate, autopsy rate, and admitting location did not change significantly during the course of the year to result in a sudden increase in the number of aspergillosis cases. The source of the outbreak was the high counts of Aspergillus conidia determined from air sampling in the non-bone marrow transplant wing during the outbreak. After high-efficiency particulate air (HEPA) filters were installed as an infection control measure, there were only two additional cases of nosocomial aspergillosis in the 2 years following the outbreak. CONCLUSIONS: This outbreak occurred among hematologic oncology patients with prolonged granulocytopenia housed in an environment with neither HEPA filters nor laminar air flow units. Our data demonstrate that in the setting of an outbreak of aspergillosis, HEPA filters are protective for highly immunocompromised patients with hematologic malignancies and are effective at controlling outbreaks due to air contamination with Aspergillus conidia.
Asunto(s)
Aire Acondicionado/métodos , Microbiología del Aire , Aspergilosis/prevención & control , Aspergillus flavus , Infección Hospitalaria/prevención & control , Filtración/métodos , Neoplasias Hematológicas/complicaciones , Huésped Inmunocomprometido , Control de Infecciones/métodos , Enfermedades Pulmonares Fúngicas/prevención & control , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Aire Acondicionado/normas , Aspergilosis/etiología , Aspergilosis/transmisión , Instituciones Oncológicas , Infección Hospitalaria/etiología , Infección Hospitalaria/transmisión , Brotes de Enfermedades/prevención & control , Brotes de Enfermedades/estadística & datos numéricos , Monitoreo del Ambiente , Femenino , Filtración/normas , Arquitectura y Construcción de Hospitales , Humanos , Control de Infecciones/normas , Enfermedades Pulmonares Fúngicas/etiología , Enfermedades Pulmonares Fúngicas/transmisión , Masculino , Persona de Mediana Edad , New York , Estudios Retrospectivos , Factores de RiesgoRESUMEN
Antagonism has been described in vitro and in vivo for azole-polyene combinations against Aspergillus species. Using an established murine model of invasive pulmonary aspergillosis, we evaluated the efficacy of several amphotericin B (AMB) dosages given alone or following preexposure to itraconazole (ITC). Mice were immunosuppressed with cortisone acetate and cyclophosphamide. During immunosuppression, animals were administered either ITC solution (50 mg/kg of body weight) or saline by oral gavage twice daily for 3 days prior to infection. Infection was induced by intranasally inoculating mice with a standardized conidial suspension (1 x 10(8) CFU/ml) of Aspergillus fumigatus strain AF 293. AMB was then administered by daily intraperitoneal injections (0.25, 0.5, 1.0, and 3.0 mg/kg) starting 24 h after inoculation and continuing for a total of 72 h. Drug pharmacokinetics of AMB and ITC in plasma were determined by high-performance liquid chromatography. Four different endpoints were used to examine the efficacy of antifungal therapy: (i) viable counts from harvested lung tissue (in CFU per milliliter), (ii) the whole-lung chitin assay, (iii) mortality at 96 h, and (iv) histopathology of representative lung sections. At AMB doses of >0.5 mg/kg/day, fewer ITC-preexposed mice versus non-ITC-preexposed mice were alive at 96 h (0 to 20 versus 60%, respectively). At all time points, the fungal lung burden was consistently and significantly higher in animals preexposed to ITC, as measured by the CFU counts (P = 0.001) and the chitin assay (P = 0.03). Higher doses of AMB did not overcome this antagonism. ITC preexposure was associated with poorer mycological efficacy and survival in mice treated subsequently with AMB for invasive pulmonary aspergillosis.
Asunto(s)
Anfotericina B/antagonistas & inhibidores , Anfotericina B/uso terapéutico , Antifúngicos/antagonistas & inhibidores , Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Itraconazol/antagonistas & inhibidores , Itraconazol/uso terapéutico , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Anfotericina B/farmacocinética , Animales , Antifúngicos/farmacocinética , Aspergilosis/microbiología , Aspergilosis/patología , Aspergilosis/prevención & control , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/aislamiento & purificación , Quimioprevención , Cortisona/administración & dosificación , Medios de Cultivo , Ciclofosfamida/administración & dosificación , Antagonismo de Drogas , Femenino , Humanos , Terapia de Inmunosupresión , Inmunosupresores/administración & dosificación , Itraconazol/farmacocinética , Pulmón/microbiología , Pulmón/patología , Enfermedades Pulmonares Fúngicas/microbiología , Enfermedades Pulmonares Fúngicas/patología , Enfermedades Pulmonares Fúngicas/prevención & control , Ratones , Pruebas de Sensibilidad MicrobianaRESUMEN
PURPOSE: To determine the optimal dose and duration of fluconazole antifungal prophylaxis therapy in bone marrow transplantation patients. SUBJECTS AND METHODS: Two hundred and fifty-three pediatric and adult bone marrow transplantation patients were randomly assigned to receive fluconazole 400 mg daily (high dose) or 200 mg daily (low dose) while they were neutropenic. After neutrophil recovery, patients were randomly assigned to receive maintenance therapy with either fluconazole (100 mg daily) or clotrimazole troches (10 mg 4 times daily) until 100 days after transplantation. Patients were monitored until 2 weeks after completion of early prophylaxis and to 100 days after transplantation. RESULTS: During the early prophylaxis phase, rates of yeast colonization and infections were similar in both treatment groups. By day 50, the incidence of Candida infections in the high-dose group was 4% (95% confidence interval [CI]: 1% to 7%; n = 5), compared with 1% in the low-dose fluconazole group (95% CI: 0% to 3%; n = 1; P = 0.08). During the same period, the incidence of Aspergillus infections was 4% (95% CI: 1% to 7%; n = 5) in the high-dose group and 2% (95% CI: 0% to 4%; n = 2; P = 0.33) in the low-dose group. During the maintenance prophylaxis phase, rates of yeast colonization and superficial infections were similar in the fluconazole and clotrimazole groups. Four patients developed systemic fungal infection in the maintenance phase (1 who received clotrimazole and 3 who received fluconazole). CONCLUSION: High-dose (400 mg daily) and low-dose (200 mg daily) fluconazole have similar efficacy in reducing the incidence of yeast colonization, superficial infection, and systemic infection in neutropenic pediatric and adult patients undergoing bone marrow transplantation. Rates of yeast colonization after neutrophil recovery were similar in patients treated with fluconazole or clotrimazole.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/prevención & control , Trasplante de Médula Ósea , Candidiasis/prevención & control , Clotrimazol/uso terapéutico , Fluconazol/uso terapéutico , Complicaciones Posoperatorias/prevención & control , Adolescente , Adulto , Anciano , Antifúngicos/administración & dosificación , Aspergilosis/mortalidad , Candidiasis/mortalidad , Niño , Preescolar , Clotrimazol/administración & dosificación , Relación Dosis-Respuesta a Droga , Femenino , Fluconazol/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/mortalidadRESUMEN
Invasive fungal infections (IFI) are increasingly diagnosed in patients undergoing allogeneic BMT. We have previously shown that the addition of metronidazole to ciprofloxacin for gastrointestinal bacterial decontamination significantly reduces the incidence of grades II-IV aGVHD by reduction of the anaerobic intestinal bacterial flora. Here, we found that the combined use of ciprofloxacin, metronidazole and fluconazole as antifungal prophylaxis increased intestinal yeast colonization when compared to ciprofloxacin and fluconazole alone (P < 0.01). Based on the EORTC criteria, a total of 18 out of 134 study patients developed IFI: seven of 68 (10%) patients who received metronidazole compared to 11 of the 66 (17%) patients decontaminated without metronidazole developed IFI (log-rank P = 0.36). Lethal IFI occurred in two of seven patients receiving metronidazole and in four of 11 patients without anaerobic decontamination. In conclusion, bacterial intestinal decontamination using metronidazole as an antibiotic with activity against most anaerobic intestinal bacteria significantly increases the intestinal yeast burden without influencing the incidence of IFI in patients undergoing allogeneic BMT.
Asunto(s)
Antibacterianos/uso terapéutico , Profilaxis Antibiótica , Antifúngicos/uso terapéutico , Trasplante de Médula Ósea , Ciprofloxacina/uso terapéutico , Fluconazol/uso terapéutico , Inmunosupresores/efectos adversos , Enfermedades Intestinales/prevención & control , Intestinos/microbiología , Metronidazol/uso terapéutico , Micosis/prevención & control , Infecciones Oportunistas/prevención & control , Premedicación , Acondicionamiento Pretrasplante/efectos adversos , Adolescente , Adulto , Aspergilosis/epidemiología , Aspergilosis/etiología , Aspergilosis/prevención & control , Bacterias Anaerobias/efectos de los fármacos , Bacterias Anaerobias/fisiología , Candidiasis/epidemiología , Candidiasis/etiología , Candidiasis/prevención & control , Causas de Muerte , Ciprofloxacina/administración & dosificación , Susceptibilidad a Enfermedades , Femenino , Fluconazol/administración & dosificación , Fungemia/epidemiología , Fungemia/etiología , Fungemia/prevención & control , Hongos/efectos de los fármacos , Hongos/patogenicidad , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/terapia , Humanos , Huésped Inmunocomprometido , Incidencia , Enfermedades Intestinales/epidemiología , Enfermedades Intestinales/etiología , Enfermedades Intestinales/microbiología , Masculino , Metronidazol/administración & dosificación , Persona de Mediana Edad , Micosis/epidemiología , Micosis/etiología , Micosis/microbiología , Neuroaspergilosis/epidemiología , Neuroaspergilosis/etiología , Neuroaspergilosis/prevención & control , Infecciones Oportunistas/epidemiología , Infecciones Oportunistas/etiología , Infecciones Oportunistas/microbiología , Estudios Prospectivos , Sobreinfección/epidemiología , Sobreinfección/etiología , Sobreinfección/microbiología , Sobreinfección/prevención & control , Resultado del TratamientoAsunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/prevención & control , Antifúngicos/uso terapéutico , Árboles , Aspergilosis/prevención & control , Candidiasis Bucal/prevención & control , Drogas en Investigación , Humanos , Enfermedades de la Boca/prevención & control , Extractos Vegetales/uso terapéuticoRESUMEN
Left-sided Aspergillus fumigatus endocarditis was established in the guinea pig heart by catheterization and inoculation with conidia via a tributary of the femoral vein. This animal model was used to compare the efficacy of the triazole antifungal agents voriconazole (UK-109,496) and itraconazole. In the prophylaxis experiments, voriconazole at a dosage of 10 mg/kg of body weight given intraperitoneally twice daily prevented A. fumigatus endocarditis in all but 1 animal (11 of 12 animals were cured). Itraconazole did not prevent Aspergillus endocarditis when it was given at the same dosage and by the same route (0 to 12 animals were cured). In the treatment experiments with 10 animals per group, voriconazole at 10, 7.5 and 5 mg/kg given orally twice daily for 7 days produced cure rates of 100, 70 and 0%, respectively. In contrast, itraconazole at 10 mg/kg given orally twice daily did not cure A. fumigatus endocarditis in the guinea pig. It is concluded that voriconazole is highly efficacious in the prevention and treatment of Aspergillus endocarditis in the guinea pig and is superior to itraconazole in these respects.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Endocarditis/tratamiento farmacológico , Itraconazol/uso terapéutico , Pirimidinas/uso terapéutico , Triazoles/uso terapéutico , Animales , Aspergilosis/prevención & control , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Endocarditis/microbiología , Endocarditis/prevención & control , Cobayas , Masculino , Pruebas de Sensibilidad Microbiana , VoriconazolRESUMEN
The efficacy of fluconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis. Therapy with fluconazole at 60 or 120 mg/kg/day was begun 24 h after lethal challenge and compared to that with amphotericin B at 1.5 mg/kg/day. Fluconazole reduced mortality compared with that in untreated controls and at 120 mg/kg/day reduced the tissue burden of A. fumigatus 10- to 100-fold in liver, kidney, and lung. However, amphotericin B was more effective in sterilizing tissues. Both fluconazole and amphotericin B dramatically decreased or eliminated circulating aspergillus antigen. Prophylaxis with fluconazole, begun 48 h before sublethal challenge, sterilized liver and kidney tissues and significantly reduced the tissue burden in lung. Early treatment with fluconazole reduced mortality and reduced antigenemia but did not sterilize tissues. Fluconazole prophylaxis at these doses prevented dissemination of invasive aspergillosis. Fluconazole was shown to have activity in the early treatment and prophylaxis of experimental invasive aspergillosis.
Asunto(s)
Aspergilosis/prevención & control , Aspergillus fumigatus , Fluconazol/uso terapéutico , Animales , Aspergilosis/tratamiento farmacológico , Aspergilosis/microbiología , Aspergilosis/mortalidad , Aspergillus fumigatus/efectos de los fármacos , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Tolerancia Inmunológica , Especificidad de Órganos , ConejosRESUMEN
Invasive pulmonary aspergillosis is a major life-threatening complication among transplant recipients and patients receiving cancer chemotherapy. In a rat model of progressive pulmonary aspergillosis that is characterized by hyphal bronchopneumonia, aerosol amphotericin B (aero-AmB; 1.6 mg/kg given 2 days before infection) significantly delayed mortality in rats compared with animals in a control group. The first death in the aero-AmB-treated group occurred on day 11, by which time seven of the eight control animals had died. The same dose of aero-AmB given as treatment (1.6 mg/kg given 24 h after infection and then daily for 6 days) was also effective. In this trial, eight of the ten animals treated with aero-AmB survived for 7 days, whereas only one of ten control animals survived. Colony counts in lung homogenates obtained 24 h after infection showed an 80-fold reduction in the number of viable spores in animals that had received 6.4-mg/kg doses of aero-AmB 2 days prior to infection. At 48 h after administering a single 1.6- or 3.2-mg/kg dose of aero-AmB, mean lung concentrations were 2.79 and 5.22 micrograms/g of tissue, respectively. We conclude, therefore, that aero-AmB kills inhaled spores and delays the progression of pulmonary aspergillosis by inhibiting mycelial proliferation.
Asunto(s)
Anfotericina B/administración & dosificación , Aspergilosis/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Aerosoles , Anfotericina B/análisis , Anfotericina B/uso terapéutico , Animales , Aspergilosis/mortalidad , Aspergilosis/prevención & control , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Inyecciones Intraperitoneales , Pulmón/análisis , Pulmón/microbiología , Enfermedades Pulmonares Fúngicas/mortalidad , Enfermedades Pulmonares Fúngicas/prevención & control , Masculino , Tamaño de los Órganos , Ratas , Ratas EndogámicasRESUMEN
Invasive fungal infections are becoming increasingly frequent among immunocompromised patients and especially among cancer patients. The most common pathogens identified are Candida species, Aspergillus species, Cryptococcus neoformans, and Mucor species. Amphotericin B remains the mainstay of antifungal therapy. However, the toxicity of this drug may limit its use and, in addition, both failures and relapses have been reported. 5-Fluorocytosine and imidazoles, such as miconazole and ketoconazole, have been shown to be active, mainly on yeast organisms. The emergence of 5-fluorocytosine-resistant strains warrants caution for its administration as a single agent. The specific role of ketoconazole has not yet been established in large studies. In our experience, ketoconazole seems to be effective in the treatment of severe oral candidiasis in non-neutropenic cancer patients. Moreover, ketoconazole administered prophylactically to neutropenic patients decreases the number of positive surveillance cultures in these patients. The rare incidence of major toxicity and the ability to administer ketoconazole orally represent also major arguments for further investigation of ketoconazole activity by prospective controlled studies.